287 related articles for article (PubMed ID: 33155402)
1. Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia.
De Pietri S; Frandsen TL; Christensen M; Grell K; Rathe M; Müller K
Pediatr Blood Cancer; 2021 Jan; 68(1):e28793. PubMed ID: 33155402
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota.
De Pietri S; Ingham AC; Frandsen TL; Rathe M; Krych L; Castro-Mejía JL; Nielsen DS; Nersting J; Wehner PS; Schmiegelow K; Hasle H; Pamp SJ; Müller K
Int J Cancer; 2020 Oct; 147(7):1953-1962. PubMed ID: 32115690
[TBL] [Abstract][Full Text] [Related]
4. Comment on: "Citrulline as a biomarker of bacteraemia during treatment for childhood acute lymphoblastic leukaemia".
Tong WH
Pediatr Blood Cancer; 2022 Mar; 69(3):e29409. PubMed ID: 34676976
[No Abstract] [Full Text] [Related]
5. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
6. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
7. [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
Schrøder H; Kjeldstad M; Boesen AM; Nielsen OJ; Schmidt KG; Johnsen HE; Gregersen H; Gustafsson G
Ugeskr Laeger; 2006 Jun; 168(26-32):2554-8. PubMed ID: 16824410
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal barrier integrity and mucosal inflammation as risk factors of blood stream infections in children treated for acute lymphoblastic leukaemia.
De Pietri S; Weischendorff S; Rathe M; Frandsen TL; Hasle H; Nersting J; Nielsen CH; Moser C; Müller K
Int J Cancer; 2023 Nov; 153(9):1635-1642. PubMed ID: 37387257
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
10. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Asberg A; Helt LR; Frandsen T; Schmiegelow K
Eur J Haematol; 2016 Feb; 96(2):160-9. PubMed ID: 25867866
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic treatment reduces circulating levels of surfactant protein-D in children with acute lymphoblastic leukemia.
Rathe M; Sorensen GL; Wehner PS; Holmskov U; Sangild PT; Schmiegelow K; Müller K; Husby S
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667327
[TBL] [Abstract][Full Text] [Related]
12. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
13. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
[TBL] [Abstract][Full Text] [Related]
14. Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy.
Lucas K; Gula MJ; Blatt J
Pediatr Hematol Oncol; 1992; 9(2):91-7. PubMed ID: 1524994
[TBL] [Abstract][Full Text] [Related]
15. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
16. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO).
Gustafsson G; Kreuger A; Clausen N; Garwicz S; Kristinsson J; Lie SO; Moe PJ; Perkkiö M; Yssing M; Saarinen-Pihkala UM
Acta Paediatr; 1998 Nov; 87(11):1151-61. PubMed ID: 9846917
[TBL] [Abstract][Full Text] [Related]
17. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N; Birgens H; Abrahamsson J; Bernell P; Griškevičius L; Hallböök H; Heyman M; Holm MS; Hulegårdh E; Klausen TW; Marquart HV; Jónsson OG; Nielsen OJ; Quist-Paulsen P; Taskinen M; Vaitkeviciene G; Vettenranta K; Åsberg A; Schmiegelow K
Eur J Haematol; 2013 May; 90(5):404-12. PubMed ID: 23461707
[TBL] [Abstract][Full Text] [Related]
18. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
[TBL] [Abstract][Full Text] [Related]
19. Comparison of myelosuppression using the D-index between children and adolescents/young adults with acute lymphoblastic leukemia during induction chemotherapy.
Matsushima S; Kobayashi R; Sano H; Hori D; Yanagi M; Kodama K; Suzuki D; Kobayashi K
Pediatr Blood Cancer; 2021 Feb; 68(2):e28763. PubMed ID: 33047887
[TBL] [Abstract][Full Text] [Related]
20. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
